Alexion Management Shakeup Continues as Four More Executives Exit
May 23 2017 - 10:08AM
Dow Jones News
By Bowdeya Tweh
Alexion Pharmaceuticals Inc. continued to turn over its top
ranks following an internal investigation into sales practices,
saying it is looking for a new chief financial officer after naming
a new one late last year.
Alexion CFO Dave Anderson, who joined the company in December
after more than a decade as CFO at Honeywell International Inc.,
plans to leave in August, the company said Tuesday. Mr. Anderson
replaced Vikas Sinha, who abruptly resigned from the role last year
along with Alexion's CEO amid an internal investigation of sales
practices.
Earlier this year, Alexion said it found senior management staff
had pressured employees to get customers to order its flagship drug
Soliris earlier than needed to meet financial targets. The
disclosure followed an investigation into allegations made by a
former employee.
The company named Ludwig Hantson as its new chief executive in
March. Mr. Hantson replaced David Brennan, who had served in an
interim capacity after former CEO David Hallal resigned.
Three other company executives -- Alexion's chief commercial
officer, its head of research and development, and its chief human
resources officer -- are also leaving the company, Alexion said
Tuesday.
Alexion said it had hired Brian Goff as its new chief commercial
officer, and that searches to replace other executives are under
way.
Shares in Alexion fell 3% to $112 in early trading.
Write to Bowdeya Tweh at Bowdeya.Tweh@wsj.com
(END) Dow Jones Newswires
May 23, 2017 09:53 ET (13:53 GMT)
Copyright (c) 2017 Dow Jones & Company, Inc.
Alexion Pharmaceuticals (NASDAQ:ALXN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Alexion Pharmaceuticals (NASDAQ:ALXN)
Historical Stock Chart
From Apr 2023 to Apr 2024